Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

SSE narrows EPS guidance, maintains long-term profit expectations

(Sharecast News) - Energy company SSE narrowed FY adjusted earnings per share guidance on Wednesday but maintained long-term profit expectations as it looks to move ahead with its renewable energy goals. SSE now expects earnings to be between 155.0p to 160.0p per share for FY25, versus previous guidance of 154.0p to 163.0p per share. It also reaffirmed its target of 175.0p to 200.0p adjusted earnings per share for FY27.

The FTSE 100-listed firm also said it plans to invest roughly £3.0bn in FY25 as part of its Net Zero Acceleration Programme Plus plan.

"This disciplined investment with a focus on value and efficiency continues to be underpinned by a strong and stable balance sheet, with adjusted net debt and hybrid capital expected to be around £10bn at 31 March 2025," said SSE.

In FY24, SSE said renewables output grew 9.8% year-on-year and now expects renewables output to have grown 17% to 13.0TWh in FY25, driven by heightened capacity and despite cold spells and stormy across the UK.

"SSE's regulated networks businesses have continued to deliver strong operational performance, with operating profit expectations for the group's other business units remaining unchanged," said SSE.

As of 0920 BST, SSE shares were up 1.25% at 1,600.31p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.